Shares of Connect Biopharma surged 7.2% to $2.38 as renewed analyst endorsements and anticipation around mid-2026 clinical data breathed life into a stock that had quietly drifted lower over the past week. The rally spotlights a familiar biotech tension: glowing price targets versus a company still burning cash and years away from revenue.
Wall Street Sees Triple-Digit Upside — But the Stock Keeps Falling Short. Three analysts covering CNTB carry a consensus "Strong Buy" with an average price target of $8.67 , implying roughly 264% upside from today's price. Cantor Fitzgerald initiated coverage with an Overweight rating and a $4.00 target , while H.C. Wainwright reiterated Buy at $7.00. Yet the stock trades at just $2.38 — a market cap of roughly $149 million — suggesting investors want proof, not projections.
The Make-or-Break Moment Arrives This Summer. Connect expects to report topline data from both Phase 2 Seabreeze STAT studies — testing its lead drug in acute asthma and COPD flare-ups — in mid-2026 . The company is targeting the emergency asthma and COPD settings in the U.S., a market with no approved biologics . That's the bull case in one sentence: if the drug works in hospital emergencies, Connect could carve out a niche that even Sanofi's $16.5 billion Dupixent franchise doesn't serve. Enrollment of the asthma study was completed in June 2026 , putting results on an imminent timeline.
Cash Is Tight, and the Clock Is Ticking. Q1 net loss widened to $19.4 million as R&D spending surged to $15.0 million, with operating cash outflow hitting $16 million . Cash stood at $46 million as of March 31, expected to fund operations into the second half of 2027 . That gives Connect roughly five quarters of runway — enough to read out data, but likely not enough to fund a Phase 3 program without raising more money and diluting existing shareholders.
One Drug, One Bet, One Outcome. Rademikibart constitutes 100% of Connect's pipeline value . A licensing deal with China partner Simcere could yield up to $110 million in remaining milestone payments , but those payouts depend on regulatory success that hasn't happened yet. The analyst optimism is real — but so is the binary risk. Positive data could validate targets three times today's price. A miss could be catastrophic for a company with no backup plan and a shrinking treasury.